Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.26 EX-10.26 First Amendment to Employment Agreement by and Between Archemix Corp. and Errol De Souza, Dated June 30, 2008
- 10.31 EX-10.31 Form of Change In Control Agreement
- 10.33 EX-10.33 Amended and Restated Collaboration Agreement by and Between Archemix Corp. and Nuvelo, Inc., Dated July 31, 2006
- 10.34 EX-10.34 Collaborative Research and License Agreement by and Between Archemix Corp. and Merck Kgaa, Dated January 17, 2007, As Amended June 6, 2007
- 10.35 EX-10.35 Collaborative Research and License Agreement Between Archemix Corp. and Merck Kgaa, Dated As of June 6, 2007 2007, As Amended June 6, 2007
- 10.36 EX-10.36 License Agreement Between Gilead Sciences, Inc. and Archemix Corp., Dated As of October 23, 2001
- 10.37 EX-10.37 Settlement Agreement and Release by and Among Archemix Corp., Gilead Sciences, Inc. and University License Equity Holdings, Inc., Dated September 4, 2003
- 10.38 EX-10.38 Amended and Restated License Agreement by and Between Archemix Corp. and Somalogic, Inc., Dated As of June 14, 2007
- 10.39 EX-10.39 License Agreement by and Between Archemix Corp. and Regado Biosciences, Inc., Dated As of October, 2003
- 10.40 EX-10.40 Collaborative Research and License Agreement by and Between Archemix Corp. and Takeda Pharmaceutical Company Limited, Dated June 11, 2007
- 10.41 EX-10.41 Collaborative Research and License Agreement by and Between Archemix Corp. and Elan Pharma International Limited, Dated June 30, 2006
- 10.42 EX-10.42 Collaborative Research, Services and License Agreement by and Between Archemix Corp. and Pfizer Inc., Dated As of December 21, 2006
- 10.43 EX-10.43 Technology Development and License Agreement by and Between Archemix Corp. and Aptamera, Inc. (Now Known As Antisoma PLC), Dated As of August 6, 2003
- 10.44 EX-10.44 Research and License Agreement by and Between Archemix Corp. and Eyetech Pharmaceuticals, Inc. (Now Known As Osi Pharmaceuticals, Inc.), Dated As of April 8, 2004
- 10.45 EX-10.45 License Agreement by and Between Archemix Corp. and Isis Pharmaceuticals, Inc., Dated As of July 23, 2007
- 10.46 EX-10.46 Exclusive License Agreement by and Between Archemix Corp. and Ophthotech Corporation, Dated As of July 31, 2007
- 10.47 EX-10.47 Feasibility Study, License and Option Agreement by and Between Archemix Corp. and Eli Lilly and Company, Dated As of August 31, 2008
- 10.48 EX-10.48 Exclusive License Agreement by and Between Archemix Corp. and Ribomic, Inc., Dated Effective As of December 10, 2007, As Amended on June 11, 2008
- 10.49 EX-10.49 Research License and Option Agreement by and Between Archemix Corp. and Ribomic, Inc., Dated Effective As of June 11, 2008
- 10.51 EX-10.51 Amdned and Restated 2001 Employee Director and Consultant Stock Plan
- 21.1 EX-21.1 Subsidiaries of Nitromed, Inc.
- 23.2 EX-23.2 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Nitromed, Inc.
- 23.3 EX-23.3 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Archemix Corp.
- 99.1 EX-99.1 Form of Proxy Card for Holders of Nitromed's Common Stock
- 99.2 EX-99.2 Consent of Cowen and Company, LLC
- 99.6 EX-99.6 Consent of Errol De Souza, PH.D. to Be Named As a Director
- 99.7 EX-99.7 Consent of Alex Barkas, PH.D. to Be Named a Director
- 99.8 EX-99.8 Consent of Peter Barrett, PH.D. to Be Named a Director
- 99.9 EX-99.9 Consent of John Maraganore PH.D. to Be Named a Director
- 99.10 EX-99.10 Consent of Michael Ross, PH.D. to Be Named a Director
Filing view
External links
Exhibit 99.2
CONSENT OF COWEN AND COMPANY, LLC
We hereby consent to the inclusion of our opinion letter, dated November 17, 2008, to the Board of Directors of NitroMed, Inc. (the “Company”) regarding the proposed merger between the Company and Archemix Corp. (“Archemix”) in the Proxy Statement/Prospectus that forms a part of the Company’s Registration Statement on Form S-4 to which this consent is filed as an exhibit (the “Registration Statement”) and to the reference in the Registration Statement to our firm and to our opinion under the headings “Summary—Opinion of NitroMed’s Financial Advisor,” “The Merger—Background of the Merger—NitroMed’s Background of the Merger,” “The Merger—Background of the Merger—Archemix’s Background of the Merger,” “The Merger—Reasons for the Merger—NitroMed’s Reasons for the Merger” and “Opinion of NitroMed’s Financial Advisor Cowen and Company, LLC.” In giving such consent, we do not admit that we come within the category of persons whose consent is required under, or that we are “experts” for purposes of, the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
Date: December 18, 2008
/s/ Cowen and Company, LLC
COWEN AND COMPANY, LLC